[Ifosfamide in combined hormonochemotherapy on prostate cancer].
In 1987, we altered the protocol of hormonochemotherapy on prostate cancer from the combination of oral UFT (futraful with uracil) and cyclophosphamide to oral UFT and intravenous ifosfamide, 3 g once a week for 3 weeks. Sixty-three patients with poorly differentiated and/or advanced prostate cancer were treated with the protocol. Although this study had no control group and the result was preliminary, prognosis of 21 patients without bone metastasis were satisfactory and none died. The 3-year survival rate of 28 patients with bone metastases less than 5 foci (EOD) was 81.3%, and that of 14 patients with multiple bone metastases was 48.8% (p < 0.001). This subclassification is useful to analyze and determine the prognosis.
Fujita
K
K
Matsushima
H
H
Nakano
M
M
Kaneko
T
T
D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000556:secondary; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage*; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D015996:Survival Rate; D005641:Tegafur / Q000008:administration & dosage; D014498:Uracil / Q000008:administration & dosage
D005641:Tegafur; D014498:Uracil; D007069:Ifosfamide